about
CD200-expressing human basal cell carcinoma cells initiate tumor growthChronic infection drives expression of the inhibitory receptor CD200R, and its ligand CD200, by mouse and human CD4 T cellsThe therapeutic promise of the cancer stem cell concept.Identification and targeting of cancer stem cells.CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaCD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma.Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Macrophages as mediators of tumor immunosurveillanceCD200R/Foxp3-mediated signalling regulates microglial activation.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Novel strategies for improved cancer vaccines.The functioning antigens: beyond just as the immunological targets.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Cell surface markers in colorectal cancer prognosis.Programmed cell removal: a new obstacle in the road to developing cancer.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?Flow cytometric analysis of CD200 expression by pulmonary small cell carcinoma.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ.Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth.Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R.Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200.CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.Cancer stem cells as targets for immunotherapy.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.CD200 Expression in Neuroendocrine Neoplasms.Are ovarian cancer stem cells the target for innovative immunotherapy?CD200 facilitates the isolation of corneal epithelial cells derived from human pluripotent stem cellsCD200:CD200R-Mediated Regulation of Immunity
P2860
Q24630272-54B7713D-A118-42B2-A022-E3713CEBF6C4Q27304435-2B1DC536-EE9F-47A8-8836-E3C048CECAC5Q33559711-F263AF44-A917-4534-A302-E925D035A365Q33921460-F93C094B-7B67-45C5-8950-D2B91E574FD1Q34171231-EEDF6313-87DF-47C0-9811-F1BF32AC555FQ34976095-BE29CA79-71AA-4C3E-AA0B-FCB5F6E6B046Q34977414-73D85513-7A9D-4AAB-9074-964803385B60Q36019782-069C1545-6459-43F9-A726-13A8ACF89E8EQ36557537-6101FFB3-8E4D-4C01-B464-8528C54C641FQ36823555-6814D582-B6BD-4BC3-A929-AAAA45E1D249Q37330271-33D8D0AA-56DD-43EA-8C9C-3CF2A352C229Q37406706-5BA1A2CA-2F7B-4F77-B981-AA5D439E96CEQ37461365-F7711339-9C53-489F-A7E2-4D1435D1E1B8Q37483795-5FC28FBB-F496-42AD-A0A1-6E378E5BCFABQ37666618-39C292E0-1F7D-4470-878C-2D065484D82EQ37845669-E17E737F-3EB6-403B-B8D0-040E60C83E8CQ37967032-EC8299A6-5926-4132-B7E2-C48C43159D34Q38108353-581CBD4E-C162-4593-87C5-3CC813604601Q38239661-24D40DEC-7A23-4D7B-B98A-8845B24DD7EFQ38941113-53826321-C702-4BF2-A4E7-8565AC9D64E3Q39313794-2AFD0B79-CBA0-4E9F-BB22-A0A9DFB1856CQ39520956-BC5BB6DC-A902-41D0-A296-990F1F02AFF3Q41127008-9A9B01AA-3B7D-4FEF-82C8-34330AD69FE7Q41888552-89D544F5-5CE0-4B74-B256-48DB018D5B96Q42196341-03C33A2A-CBA6-4EAD-BC15-9D0828F2D4ADQ46826314-5AA62F6F-A937-4962-AFF5-AB74B8C2087BQ47637581-2F444621-105E-4EF4-91FE-11B6E7EECC56Q48278683-D835FE7A-8C8C-4587-ADA7-D4F559806C97Q48958626-84857C30-9C4D-4E97-A0E3-F1720738C8B2Q51805000-3455DA7E-CCDC-4796-AD3A-89CE84D21125Q55164226-4F79297F-D63F-4CC8-BBAC-1CDB9DED4F11Q58589538-AA501FC4-FE34-4B07-AEC0-7EBC5797E938Q58692091-DC333D68-E811-444C-8D6D-6B3EC1838E2F
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cancer stem cells, CD200 and immunoevasion.
@en
type
label
Cancer stem cells, CD200 and immunoevasion.
@en
prefLabel
Cancer stem cells, CD200 and immunoevasion.
@en
P356
P1433
P1476
Cancer stem cells, CD200 and immunoevasion.
@en
P2093
Brian T Kawasaki
William L Farrar
P304
P356
10.1016/J.IT.2008.07.005
P577
2008-09-03T00:00:00Z